Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APVO436 in Relapsed/Refractory AML or MDS
NCT03647800Phase 1Unknown
- Sponsor
- Aptevo Therapeutics
- Start
- Dec 2018
- Primary completion
- Dec 2022
- Modality
- Prophylactic Vaccines, Antibody Conjugates, Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of mipletamig in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (6 arms), sponsored by Aptevo Therapeutics. Primary endpoints: Recommended Phase 2 Dose at 35 days and Safety and Tolerability at 35 days. Status: unknown.
02
Drugs
mipletamig
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT03647800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03647800.